Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 18;10(8):1763.
doi: 10.3390/jcm10081763.

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities

Marta Mazzetti  1   2 , Giulia Marconi  1 , Martina Mancinelli  1 , Antonio Benedetti  1 , Marco Marzioni  1 , Luca Maroni  1
Affiliations
Review

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities

Marta Mazzetti et al. J Clin Med. .

Abstract

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two chronic cholestatic liver diseases affecting bile ducts that may progress to biliary cirrhosis. In the past few years, the increasing knowledge in the pathogenesis of both diseases led to a growing number of clinical trials and possible new targets for therapy. In this review, we provide an update on the treatments in clinical use and summarize the new drugs in trials for PBC and PSC patients. Farnesoid X Receptor (FXR) agonists and Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists are the most promising agents and have shown promising results in both PBC and PSC. Fibroblast Growth Factor 19 (FGF19) analogues also showed good results, especially in PBC, while, although PBC and PSC are autoimmune diseases, immunosuppressive drugs had disappointing effects. Since the gut microbiome could have a potential role in the pathogenesis of PSC, recent research focused on molecules that could change the microbiome, with good results. The near future of the medical management of these diseases may include new treatments or a combination of multiple drugs targeting different signaling pathways at different stages of the diseases.

Keywords: Farnesoid X Receptor (FXR) agonist; Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists; clinical trials; primary biliary cholangitis (PBC); primary sclerosing cholangitis (PSC); ursodeoxycholic acid (UDCA).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Current algorithm of the treatment in PBC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Association for the Study of the Liver Electronic address eee, European Association for the Study of the L: EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 2017;67:145–172. doi: 10.1016/j.jhep.2017.03.022. - DOI - PubMed
    1. Beuers U., Trauner M., Jansen P., Poupon R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J. Hepatol. 2015;62(Suppl. 1):S25–S37. doi: 10.1016/j.jhep.2015.02.023. - DOI - PubMed
    1. Wagner M., Fickert P. Drug Therapies for Chronic Cholestatic Liver Diseases. Annu. Rev. Pharmacol. Toxicol. 2020;60:503–527. doi: 10.1146/annurev-pharmtox-010818-021059. - DOI - PubMed
    1. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006;3:318–328. doi: 10.1038/ncpgasthep0521. - DOI - PubMed
    1. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525–531. doi: 10.1053/jhep.2002.36088. - DOI - PubMed